**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE 150 mg & ZIDOVUDINE 300 mg TABLETS USP | | REF. NO: NDQD201508163 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each film coated tablet contains: Lamivudine USP 150 mg and Zidovudine USP 300 mg. | |
| **BATCH NO.:** DLC7330A | **PRESENTATION:** |  | |
| **MGF. DATE:** Aug. 2013 | **MANUFACTURER:** | MACLEODS Pharmaceuticals. | |
| **EXP. DATE:** Jul. 2016 | **ADDRESS:** | Plot No. 25-27, Survey No. 366, Premier Ind. Estate, Kachigam, Daman - 396 210, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC:HPLC | Adopted In - House Method | RT of the component peaks in the assay sample preparation corresponds to that in the assay standard preparation | Super-imposable peak at RT 2.9 and 3.8 Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In - House Method | No tablet less than 80.0% [n=6] |  | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In - House Method | No tablet less than 80.0% [n=6] | Lamivudine 90.7% (RSD = 1.4%; n = 6) | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In - House Method | No tablet less than 80.0% [n=6] |  | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In - House Method | No tablet less than 80.0% [n=6] | Zidovudine 89.1% (RSD = 0.3%; n = 6) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In - House Method | 90.0 -110.0% |  | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In - House Method | 90.0 -110.0% | Lamivudine 98.5% (RSD = 0.6%; n = 9) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In - House Method | 90.0 -110.0% |  | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In - House Method | 90.0 -110.0% | Zidovudine 96.0% (RSD = 0.8%; n = 9) | **COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | DATE: |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-05-2015 |